Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 6/20 | 0.41 |
| ▸ | LSS | P48449 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25268467 | 0.90 | — | — | |
| SCHEMBL31602260 | 0.90 | FUCA1 (0.37) | ALDH1A1ALOX5GBA1LSSSPHK1 | |
| SCHEMBL29363158 | 0.85 | ALDH1A1 (0.50) | ALDH1A1ALOX5GBA1LSSSPHK1 | |
| SCHEMBL10456643 | 0.85 | EPHX1 (0.45) | ALDH1A1ALOX5GBA1LSSSPHK1 | |
| SCHEMBL6719013 | 0.85 | EPHX1 (0.45) | ALDH1A1ALOX5GBA1LSSSPHK1 | |
| SCHEMBL20880673 | 0.82 | TRPV1 (0.45) | — | |
| SCHEMBL5227653 | 0.81 | CYP1A2 (0.47) | LSSEPHX1 | |
| SCHEMBL13095873 | 0.81 | CYP1A2 (0.47) | LSSEPHX1 | |
| SCHEMBL16974802 | 0.81 | CYP1A2 (0.47) | LSSEPHX1 | |
| SCHEMBL12166486 | 0.80 | CYP1A2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175519-A1 | AMPHIPHILIC CYCLOBUTENES AND CYCLOBUTANES | NUTECH VENTURES | 2015-06-25 | — | — | US | disclosed |
| EP-2855415-A1 | AMPHIPHILIC CYCLOBUTENES AND CYCLOBUTANES | Nutech Ventures, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013181155-A1 | AMPHIPHILIC CYCLOBUTENES AND CYCLOBUTANES | NUTECH VENTURES (US) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175519-A1 | AMPHIPHILIC CYCLOBUTENES AND CYCLOBUTANES | FNTB, ABCB4, ALG1 | ALDH1A1 4301/4885ALOX5 205/4885GBA1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.